



BTOG Masterclass on Stage III NSCLC

Thursday 3rd December 2020

17:30 to 18:30

Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) CPD credit (code: 133530)

Chair: Dr Tom Newsom-Davis – BTOG Steering Committee Vice-Chair

17:30	Welcome	Dr Tom Newsom-Davis
17:30	Chemo-Radiotherapy and consolidation IO Update	Prof Corinne Faivre-Finn
17:45	Q&A	
17:50	Peri-operative Immunotherapy Update	Prof Samreen Ahmed
18:05	Q&A	
18:10	Novel Agents Update	Dr Alastair Greystoke
18:25	Q&A	
18:30	Close	

Biographies

Dr Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group and led the RM Partners Cancer Vanguard lung pathway. Dr Newsom-Davis is actively involved in clinical research and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.

Professor Samreen Ahmed - I have been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine London. I have a research degree (MD) through Nottingham University and undertook Oncology training in Western Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. I am a Fellow of the Royal College of Physicians. I am Training Programme Director for Medical Oncology. I am the research Lead for both breast and lung cancer in the East Midlands Cancer Network. I work with the National Cancer Research Network as a trialist.

Dr Alastair Greystoke is Clinical Senior Lecturer and Honorary Consultant at the Newcastle University and the Northern Centre for Cancer Care. Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition, he is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in NSCLC), Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

Prof Corinne Faivre-Finn is an Honorary Consultant Oncologist and a Professor of Thoracic Radiation Oncology at The University of Manchester with an interest in lung cancer. She trained in Paris until 1998 and took a consultant post at The Christie in 2001. She was appointed as Professor of Thoracic Radiation Oncology at the University of Manchester in 2015. Prof Faivre-Finn is an active member of several national and international research committees.